(0.30%) 5 146.75 points
(0.29%) 38 554 points
(0.41%) 17 920 points
(-0.76%) $83.21
(2.13%) $1.964
(-0.18%) $2 342.90
(1.15%) $27.57
(0.64%) $928.00
(-0.25%) $0.932
(-0.21%) $11.00
(-0.33%) $0.798
(0.64%) $92.46
@ $19.46
Išleistas: 14 vas. 2024 @ 16:30
Grąža: 2.67%
Ankstesnis signalas: vas. 13 - 16:31
Ankstesnis signalas:
Grąža: -3.52 %
Live Chart Being Loaded With Signals
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases...
Stats | |
---|---|
Šios dienos apimtis | 355 716 |
Vidutinė apimtis | 692 466 |
Rinkos kapitalizacija | 1.23B |
EPS | $0 ( 2024-02-27 ) |
Kita pelno data | ( $-0.0900 ) 2024-05-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.61 |
ATR14 | $0.0250 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-09 | Cornelissen Bart Jan | Buy | 190 194 | Stock Option (Right to Buy) |
2024-04-09 | Cornelissen Bart Jan | Buy | 42 265 | Common Stock |
2024-04-09 | Cornelissen Bart Jan | Buy | 0 | |
2024-03-11 | Kuch John J | Sell | 849 | Common Stock |
2024-03-11 | Eckert Celia | Sell | 850 | Common Stock |
INSIDER POWER |
---|
65.94 |
Last 96 transactions |
Buy: 2 831 480 | Sell: 458 022 |
Tūris Koreliacija
Xencor Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
THRX | 0.898 |
WDC | 0.891 |
PALT | 0.886 |
TREE | 0.883 |
OZKAP | 0.882 |
OTRK | 0.881 |
XPEL | 0.873 |
HLMN | 0.871 |
MBIO | 0.869 |
TCBIO | 0.862 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Xencor Inc Koreliacija - Valiuta/Žaliavos
Xencor Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $168.34M |
Bruto pelnas: | $156.84M (93.17 %) |
EPS: | $-2.08 |
FY | 2023 |
Pajamos: | $168.34M |
Bruto pelnas: | $156.84M (93.17 %) |
EPS: | $-2.08 |
FY | 2022 |
Pajamos: | $164.58M |
Bruto pelnas: | $155.78M (94.65 %) |
EPS: | $-0.930 |
FY | 2021 |
Pajamos: | $275.11M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $1.440 |
Financial Reports:
No articles found.
Xencor Inc
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.